CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 26 enrolled
Drug / intervention
Memantine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05796752
NCT05796752Phase 3Active

Single-Group Crossover Trial Comparing Behavioral Treatment to Memantine in Body Focused Repetitive Behaviors

University of Chicago·interventional·Posted Apr 3, 2023·Updated Jun 11, 2026

In Brief

A Phase 3 clinical trial evaluating Memantine and ComB Behavioral Therapy for Skin-Picking and Trichotillomania (Hair-Pulling Disorder). Active but no longer recruiting, targeting 26 participants across 1 site.

Detailed Summary

The goal of the proposed study is to compare the efficacy of behavioral treatment (BT) to memantine, a psychopharmacological agent, for BFRBs. 28 subjects with trichotillomania (TTM) or skin picking disorder (SPD) will receive 8 weeks of memantine treatment, followed by 8 weeks of comprehensive behavioral therapy (ComB) treatment. The hypothesis to be tested is that behavioral therapy will be associated with superior clinical outcomes as compared to memantine. A second hypothesis is that both memantine and behavioral therapy will demonstrate improvement from baseline to the respective posttreatment assessment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3ActiveOverdue
202420252026
First PostedApr 3, 2023
Enrollment StartAug 2, 2023
Primary CompletionJun 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 3.2 years ago

Interventions

Memantinedrug

Cognition-enhancing medication

ComB Behavioral Therapybehavioral

Therapy for BFRBs